Introduction nated. 12, [20] [21] [22] Peritoneal dissemination is a common clinical situation in
The present report investigates the feasibility of an oncology which usually results from ovarian or digestive HSVtk-based suicide gene therapy in a model of peritoprimary neoplasms. 1 Surgical resection of extensive perneal carcinomatosis induced by DHD/K12 colorectal itoneal carcinomatosis is impossible and most of these adenocarcinoma cells in BD-IX syngeneic rats. Following cancers, including colorectal carcinomas, are poorly intraperitoneal injection of DHD/K12 cells transduced reactive to systemic chemotherapy. Intraperitoneal with the HSVtk gene, treatment with GCV drastically delivery of cytotoxic drugs which allows high local reduces the tumor burden and statistically improves concentration could lead to clinical benefits in some survival. circumstances. 1, 2 Suicide gene therapy consists of the intracellular delivResults ery of a gene coding for an enzyme which transforms a prodrug into a cytotoxic product. 3 Thymidine kinase from the herpes simplex virus type I (HSV-TK) is the Ganciclovir cytotoxicity for HSV-TK-expressing DHD/K12 most commonly used enzyme. It phosphorylates the cells nucleoside analogue ganciclovir (GCV) and allows its Rat colorectal adenocarcinoma DHD/K12 cells were further transformation, after subsequent phosphorylation transduced in vitro with a retroviral vector containing the by cellular kinases, into cytotoxic ganciclovir-tri-phosthymidine kinase gene from HSV-1 under the control of phate, which inhibits cellular DNA polymerase. [4] [5] [6] the SV40 promoter (DHD/K12-TK). PCR on genomic Numerous in vitro and in vivo studies have demonstrated DNA and RT-PCR on total RNA confirmed that the that tumor cells expressing HSV-TK are specifically killed HSVtk gene was integrated and expressed in the infected by the antiviral drug GCV. [7] [8] [9] [10] [11] Moreover, untransduced DHD/K12-TK cells (data not shown and Figure 1 ). adjacent cells are also sensitive to the GCV cytotoxic
The cytotoxicity of increasing concentrations (0.1-5 effect ('bystander effect'). 10, [12] [13] [14] For in vivo transduction, m) of the prodrug GCV was then tested on the the suicide gene is, in most cases, inserted into a viral DHD/K12-TK cells. Figure 2 shows that GCV concenvector which is directly injected at the tumor site. [14] [15] [16] [17] [18] [19] trations as low as 0.5 m killed the majority of these cells Several clinical studies currently underway are based on while untransfected DHD/K12 cells were resistant to a similar approach. 3 Alternatively, several investigators much higher concentrations. The IC 50 is 0.4 m for have envisaged the delivery of the gene therapy to the DHD/K12-TK cells and 82 m for untransfected cells (data not shown).
Bystander effect between DHD/K12-TK and DHD/K-12 5) . Two rats were injected at day 0 with untransduced DHD/K12 cells while groups of two animals were injected with DHD/K12-TK cells. These last groups injected with DHD/K12-TK cells were then treated intraperitoneally with increasing doses of GCV for 5 days from day 14 to test the efficiency and safety of the method. The animals were killed at day 21 and the reduction of the tumor volume was assessed by direct differences in efficacy with treatments prolonged up to 14 days. Moreover, we did not observe any obvious toxtransfected DHD/K12 cells were cocultured and chalicity of GCV at doses ranging from 35 mg/kg once a day lenged for 7 days with GCV at a concentration that kills to 150 mg/kg once a day or 75 mg/kg twice a day (data 100% of DHD/K12-TK cells and does not affect untransnot shown). The dose of GCV for further treatment was fected cells (20 m) ( Figure 3 ). Under these experimental thus fixed at 150 mg/kg injected intraperitoneally once a conditions, the presence of 25% of DHD/K12-TK cells day for 5 days starting at day 14. Similar or higher doses was sufficient to induce a cytotoxic effect which killed had previously been administered by others without any 89% of the cells. This experiment also confirmed that the detectable toxicity.
14 survival of untransfected DHD/K12 cells was unaffected Animals were then injected with various proportions by the GCV treatment.
of DHD/K12-TK and untransfected DHD/K12 cells and treated with GCV using the same protocol. Eight rats In vivo model for suicide gene therapy of peritoneal were analyzed for each proportion of transduced/ carcinomatosis untransduced cells. The eight rats injected with 0% A model of peritoneal carcinomatosis induced by DHD/K12-TK cells died between days 50 and 56 (median DHD/K12 cells in syngeneic BD-IX rats was chosen to survival: 53 days) ( Figure 5 ) as did the control animals test the feasibility of an HSVtk-based gene therapy treated with the buffer alone (data not shown). Animals approach. BD-IX rats were injected intraperitoneally at injected with 20% of DHD/K12-TK cells and treated with day 0 with 10 6 DHD/K12-TK cells or with 10 6 untrans-GCV showed a significantly prolonged survival as comduced DHD/K12 cells. These animals developed peritopared with the animals injected with 0% DHD/K12-TK neal tumor nodes on the epiploon within 10 days and 
Figure 2 Cytotoxic effect of ganciclovir on DHD/K12-TK cells in vitro. Stably transfected DHD/K12-TK cells and untransfected DHD/K12 cells

Figure 3 In vitro bystander effect between DHD/K12-TK and untransfected cells. DHD/K12-TK cells and untransfected cells were cocultured were treated in vitro for 7 days with increasing concentrations of GCV. Cell viability was estimated with the WST-1 test. The concentrations of in various proportions as indicated. These cocultures were treated with 20 m of GCV for 7 days and cell viability was measured with the WST-GCV which killed 50% of the cells (IC
Figure 4 Ganciclovir treatment of rats injected with DHD/K12-TK cells. The figure shows the peritoneal cavity at day 21 of a rat injected with DHD/K12 untransfected cells and treated with GCV (a), a rat injected with DHD/K12-TK cells and treated with the HBSS buffer alone (b), and a rat injected with DHD/K12-TK cells and treated with GCV for 5 days at 150 mg/kg (c). Groups of two rats were injected with DHD/K12 or DHD/K12-TK cells and treated with GCV for 5 days at doses from 35 mg/kg once a day to 150 mg/kg once a day or 75 mg/kg twice a day. The animals were killed at day 21 and a representative picture is shown in the figure. The letter 'T' indicates the peritoneal tumor nodes.
cells (log-rank test: P Ͻ 0.01). Animals injected with 50% of DHD/K12-TK cells again showed a significantly prolonged survival following GCV treatment as compared with the 0% DHD/K12-TK group (P Ͻ 0.05). Indeed, in each of the 20% and 50% DHD/K12-TK groups, a small number of animals (12.5 and 25%, respectively) showed a prolonged survival and were tumor-free at day 270. Moreover, the rats injected with 100% DHD/K12-TK cells showed a significant increase in survival after a single 5-day treatment with GCV (P Ͻ 0.01) ( Figure 5 ). In this last group, three animals (37.5%) showed a long survival and were free of tumors at day 270. Surgical wounds favor the implantation of tumor cells in the peritoneal cavity and the development of tumor nodes. To reproduce the surgical procedure, rats were laparotomized and a dissection of the sigmoid area was performed without any intestinal resection. 10 6 injections of GCV for 5 days starting at day 14. Rats injected with 100% DHD/K12-TK cells and treated with GCV showed a major reduction of their tumor nodes as compared with control animals treated with the buffer Low expression of the transgene in relapsing tumors Following a 5-day GCV treatment, a dramatic reduction alone (data not shown). Animals injected with 0% DHD/K12-TK cells and treated with GCV or rats treated of the tumor burden as well as a significant increase in the median survival was observed in all groups injected, with the buffer alone died between days 53 and 63 (median survival: 56 days) ( Figure 5 and data not shown) .
Figure 5 Survival of rats injected with DHD/K12-TK
either directly or after peritoneal irritations, with 100% DHD/K12-TK cells. However, only a minority of these Animals injected with 20% DHD/K12-TK cells and treated with GCV showed an increased survival as comanimals showed a complete response with most relapsing and finally dying of tumor progression. The expression pared to animals injected with 0% DHD/K12-TK cells (log-rank test: P Ͻ 0.05). The animals injected with 50% of HSV-TK in tumor nodes after relapse and death by tumor progression was investigated by RT-PCR followed DHD/K12-TK cells did not survive longer than control animals, while animals injected with 100% DHD/K12-TK by Southern blotting revealed by a TK probe (Figure 1 ). Tumor samples were collected from animals injected cells had a significantly longer survival (P Ͻ 0.0001). One animal from the 20% DHD/K12-TK cell group (12.5%) with 20, 50 or 100% DHD/K12-TK cells after peritoneal irritation or not. Only a single tumor node from an aniand three animals from the 100% DHD/K12-TK cell group (42.8%) were still alive and tumor-free at day 308.
mal injected with 100% DHD/K12-TK cells showed a
Figure 7 Survival of rats injected with DHD/K12-TK cells and treated Figure 6 Survival of rats injected with DHD/K12-TK cells after perito-
with repeated cycles of ganciclovir. As described in Figure 5, transduction to peritoneal cells and could therefore be suitable for such pathological conditions. strong expression of the HSV-TK mRNA although this
In this article, the feasibility of an HSVtk-mediated expression was much lower than in the original gene therapy for peritoneal carcinomatosis induced by DHD/K12-TK cells (Figure 1 , compare lanes + and 6; 4 colorectal adenocarcinoma cells has been investigated in l of the RT-PCR reaction were loaded on lane + while a syngeneic immunocompetent animal model. BD-IX rats 20 l were loaded on all the other lanes). All the other which had developed peritoneal carcinomatosis induced tumor nodes showed a weak but still detectable HSV-TK by DHD/K12 cells expressing the tk gene showed a proexpression (lanes 1-5). Thus it is likely that relapsing longed survival after GCV treatment when compared tumor nodes still contained a low number of cells which with animals injected with tumor cells which do not can still express the tk gene.
express the tk gene or with animals treated with the buffer alone. Although most animals relapsed and finally Repeated ganciclovir courses died of tumor progression, 35-40% of them demonstrated To improve the efficiency of the therapy, rats injected a long survival and remained tumor-free. These data thus with various proportions of DHD/K12-TK and untransindicated that a combined TK-GCV approach is efficient duced DHD/K12 cells were treated by repeated 5-day in this model and could be considered for the treatment cycles of GCV (150 mg/kg, once daily). The first treatof peritoneal carcinomatosis. Our observation supports ment was administered for 5 days at day 14 as in the that of several groups who have developed different experiment described above ( Figure 5 ) and was followed animal models for gene therapy of peritoneal carcinoby additional 5-day GCV cycles repeated every 4 weeks matosis. 12, [20] [21] [22] ( Figure 7) . The group injected with 20% DHD/K12-TK It is generally considered that, after in vivo gene transcells showed no significantly longer survival after duction, only a small proportion of tumor cells captures repeated GCV cycles but the groups injected with 50 or the transgene. Therefore, the potential efficiency of an in 100% DHD/K12-TK cells showed a significant increase of vivo tk gene therapy relies on the 'bystander effect'. As survival (log-rank test: P = 0.015 and Ͻ0.01, respectively) demonstrated in this article, DHD/K12 colon cancer cells when compared with animals injected with untransduced do exhibit a bystander effect in vitro. Consistent with this cells only. However, repeated GCV treatments did not observation, the animals injected with 20 or 50% generate any survival advantage as compared with a DHD/K12-TK cells mixed with untransfected DHD/K12 single cycle ( Figure 5 ). Again, one of five animals from cells showed a significantly increased survival as comthe 50% DHD/K12-TK group and two of five animals pared with rats injected with DKD/K12 control cells. from the 100% DHD/K12-TK group experienced a long Indeed, in the 20 or 50% DHD/K12-TK groups, a few survival and were alive and tumor-free at day 130.
animals (10-20%) showed a prolonged survival and remained apparently tumor-free. Several mechanisms can account for an in vivo bystander effect: a diffusion of Discussion the phosphorylated GCV from cell to cell through the gap junctions, the phagocytosis of apoptotic vesicles by adjacPeritoneal carcinomatosis is a common clinical situation which, in most cases, cannot be eradicated by surgery or ent cells, or an antitumor immune reaction. 12, 14, [23] [24] [25] Therefore, we could conclude either that the GCV chemotherapy. There is, therefore, an urgent need for novel therapeutic approaches. Intraperitoneal suicide therapy allowed a complete eradication of DHD/K12 cells in these animals showing prolonged survivals or gene delivery should make it possible to confine gene that a few animals developed an immune reaction which tissue culture dish in the presence of polybrene (8 g/ml). After 150 min of incubation at 37°C, 7 ml of fresh eliminated residual tumor cells. BD-IX rats are immunocompetent but DHD/K12 cells are considered to be poorly medium was added to the cells. Twenty-four hours later, the cells were diluted and selected for 2 weeks in the immunogenic and even immunosuppressive. 26 It is however possible that the long-term survivors developed a presence of G418 (active concentration: 500 g/ml). specific antitumor immune reaction. Further experiments are needed in order to evaluate the immunity of these RT-PCR for HSV-TK expression animals and to determine if immunomodulation could TK expression in stably transduced DHD/K12 clones and increase their survival rates.
in tumor nodes was investigated by RT-PCR. Tumor RT-PCR performed on relapsing tumor nodes detected nodes were harvested from animals freshly dead from a weak TK expression. It is thus likely that these tumors extensive peritoneal dissemination. Total cellular RNA contained a large majority of cells that did not express was extracted by Tripure reagent (Boehringer the tk gene mixed with a low number of transgeneMannheim). One microgram of RNA was first reverse expressing cells. The failure of repeated GCV treatments transcribed (MoMLV reverse transcriptase, GIBCO BRL) suggests that the number of TK-expressing cells in these with a specific TK-3′ primer (5′-ACAGGGTAAArelapsing tumors is insufficient to generate a bystander TAACGTGTC-3′). The cDNA product was then amplified effect and a tumor shrinkage. When in vivo transduction with the TK primers 5′-ATGGCTTCGTACCCCTG-3′ and is performed, repeated injections of the transgene-con-5′-AAGGTCGGCGGGATGAG-3′. The amplification was taining vector will probably be required in order to mainperformed for 35 cycles (denaturation at 95°C for 1 min, tain a significant number of cells expressing the tk gene.
annealing at 50°C for 1 min and elongation at 72°C for 2 In this paper, cells were transduced in vitro before animin) followed by a 4-min final elongation at 72°C. The mal injections. Such an approach is not applicable in most RT-PCR products were transferred to a nylon membrane clinical settings and experiments are in progress in our (Quiabrane; Qiagen, Hilden, Germany) and analyzed by laboratory to develop appropriate techniques for in vivo Southern blotting. The TK-DNA probe was the 32 P rangene delivery. Indeed, the model we describe here is suitdom labeled RT-PCR product from stably transfected able for the investigation of intraperitoneal delivery of DHD/K12-TK cells. suicide genes in immunocompetent animals.
Animal treatment
Materials and methods
BD-IX rats were injected intraperitoneally at day 0 with 10 6 cells and then treated by intraperitoneal injections of Cell lines and in vitro treatment GCV diluted in Hank's balanced salt solution (HBSS; DHD/K12/Prob cells 27 were cultured in DMEM-modi-GIBCO BRL) or injections of the HBSS buffer alone for 5 fied Dulbecco's medium (GIBCO BRL, Frederick, MD, days starting at day 14. In the experiment described in USA) supplemented with 5% fetal bovine serum (FBS), Figure 4 , the animals were killed at day 21 and the tumor 1% glutamine 200 mm, 1% Hepes 1 m, 1% arginine 0.55 dissemination was evaluated by direct abdominal exammm and antibiotics. To test GCV cytotoxicity, 5 × 10 3 cells ination. In the other experiments, animals were allowed were incubated in 200 l of medium plus 15% FBS on 96-to die from extensive peritoneal disease and survival well plates. GCV (Cymevene; Syntex Laboratories, Palo curves were drawn. Alto, CA, USA) was diluted in sterile water and added
In the experiment described in Figure 7 , 5-day GCV to the culture medium to reach the concentrations inditreatments (150 mg/kg once daily) were repeated every cated in the figures. Cells were treated with GCV for 7 4 weeks. days and the medium + GCV was replaced at days 4 For the peritoneal irritations, the animals were laparoand 6.
tomized and a dissection of the sigmoid was performed To test the bystander effect, DHD/K12-TK cells and without any intestinal resection. untransfected cells were cocultured in various proportions (0, 2.5, 5, 7.5, 10, 15, 25 and 50% of DHD/K12-TK cells, respectively). These cocultures were then chalStatistics lenged with 20 m of GCV for 7 days.
Kaplan-Meier curves were established for each group After 7 days of treatment, cell viability was tested with and survivals were compared with the log-rank test. the WST-1 cell proliferation reagent as recommended by the manufacturer (Boehringer Mannheim, Mannheim, Germany).
